Chemical Compound Review:
SureCN94663 (4R)-4-benzyl-6-(3H-imidazol- 4-ylmethyl)-3...
Synonyms:
CHEMBL351706, SureCN134853, CHEBI:374775, BMS-214662, CID448545, ...
Vite,
Rose,
Seiden,
Schmidt,
Marzo,
Giraldo,
Puchlaski,
Mitt,
Dona B. Alberti,
Fuchs,
Daniel L. Mulkerin,
Robert E. Martell,
Bhide,
Baselga,
Lombardo,
Kantarjian,
Guo,
Ding,
Faderl,
Bednarz,
Supko,
Kim,
Lasierra,
Gullo-Brown,
Leftheris,
Manne,
Carulla,
Anel,
Gómez-Benito,
Gullo-Brown,
Van Vreckem,
Tabernero,
Howard H. Bailey,
Ricca,
Valverde,
Dancey,
Chong,
Voi,
Rubio-Félix,
Marco M. Gottardis,
Giles,
Beran,
Felip,
García,
Garcia-Manero,
Del Campo,
Eder,
Fairchild,
Lee,
Larrad,
Amrein,
Vite,
Cooper,
Batorsky,
James P. Thomas,
Ferrajoli,
Naval,
Bai,
Bellmunt,
Guix,
Rojo,
Patel,
Kurzrock,
Pérez-Galán,
Penhallow,
O'Brien,
Lynch,
Manning,
Hunt,
Slusarchyk,
Wong,
Cho,
Kimberly A. Binger,
Clark,
Manne,
Smykla,
Miller,
Koller,
Andreu,
Chao,
Manne,
Wen,
Thomas,
Bol,
Hunt,
Cortes,
Lee,
Estey,
López-Royuela,
Marimón,
Albanell,
Yu,
Garrido,
George Wilding,
Ryan,
Vázquez,
Wright,
Sonnichsen,
- Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. Cortes, J., Faderl, S., Estey, E., Kurzrock, R., Thomas, D., Beran, M., Garcia-Manero, G., Ferrajoli, A., Giles, F., Koller, C., O'Brien, S., Wright, J., Bai, S.A., Kantarjian, H. J. Clin. Oncol. (2005)
- Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Rose, W.C., Lee, F.Y., Fairchild, C.R., Lynch, M., Monticello, T., Kramer, R.A., Manne, V. Cancer Res. (2001)
- A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Mackay, H.J., Hoekstra, R., Eskens, F.A., Loos, W.J., Crawford, D., Voi, M., Van Vreckem, A., Evans, T.R., Verweij, J. Clin. Cancer Res. (2004)
- Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Morgan, M.A., Ganser, A., Reuter, C.W. Leukemia (2003)
- Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. Tabernero, J., Rojo, F., Marimón, I., Voi, M., Albanell, J., Guix, M., Vázquez, F., Carulla, J., Cooper, M., Andreu, J., Van Vreckem, A., Bellmunt, J., Manne, V., Manning, J.A., Garrido, C., Felip, E., Del Campo, J.M., García, M., Valverde, S., Baselga, J. J. Clin. Oncol. (2005)
- Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. Manne, V., Lee, F.Y., Bol, D.K., Gullo-Brown, J., Fairchild, C.R., Lombardo, L.J., Smykla, R.A., Vite, G.D., Wen, M.L., Yu, C., Wong, T.W., Hunt, J.T. Cancer Res. (2004)
- BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Copland, M., Pellicano, F., Richmond, L., Allan, E.K., Hamilton, A., Lee, F.Y., Weinmann, R., Holyoake, T.L. Blood (2008)
- Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Gómez-Benito, M., Marzo, I., Anel, A., Naval, J. Mol. Pharmacol. (2005)
- Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Ryan, D.P., Eder, J.P., Puchlaski, T., Seiden, M.V., Lynch, T.J., Fuchs, C.S., Amrein, P.C., Sonnichsen, D., Supko, J.G., Clark, J.W. Clin. Cancer Res. (2004)
- Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Marzo, I., Pérez-Galán, P., Giraldo, P., López-Royuela, N., Gómez-Benito, M., Larrad, L., Lasierra, P., Rubio-Félix, D., Anel, A., Naval, J. Leukemia (2004)
- Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Kurzrock, R., Cortes, J., Kantarjian, H. Semin. Hematol. (2002)
- A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Dy, G.K., Bruzek, L.M., Croghan, G.A., Mandrekar, S., Erlichman, C., Peethambaram, P., Pitot, H.C., Hanson, L.J., Reid, J.M., Furth, A., Cheng, S., Martell, R.E., Kaufmann, S.H., Adjei, A.A. Clin. Cancer Res. (2005)
- Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Reid, T.S., Beese, L.S. Biochemistry (2004)
- Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. Hunt, J.T., Ding, C.Z., Batorsky, R., Bednarz, M., Bhide, R., Cho, Y., Chong, S., Chao, S., Gullo-Brown, J., Guo, P., Kim, S.H., Lee, F.Y., Leftheris, K., Miller, A., Mitt, T., Patel, M., Penhallow, B.A., Ricca, C., Rose, W.C., Schmidt, R., Slusarchyk, W.A., Vite, G., Manne, V. J. Med. Chem. (2000)
- Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Bailey, H.H., Alberti, D.B., Thomas, J.P., Mulkerin, D.L., Binger, K.A., Gottardis, M.M., Martell, R.E., Wilding, G. Clin. Cancer Res. (2007)
- Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. Cesario, A., Catassi, A., Festi, L., Imperatori, A., Pericelli, A., Galetta, D., Margaritora, S., Porziella, V., Cardaci, V., Granone, P., Dominioni, L., Russo, P. Clin. Cancer Res. (2005)
- Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Gau, C.L., Kato-Stankiewicz, J., Jiang, C., Miyamoto, S., Guo, L., Tamanoi, F. Mol. Cancer Ther. (2005)
- Agents targeting ras signaling pathway. Dancey, J.E. Curr. Pharm. Des. (2002)